Pharmacists can educate patients about staying up to date on immunizations and discuss fall prevention strategies.
Publication|Articles|October 15, 2025
Pharmacy Practice in Focus: Oncology
- October 2025
- Volume 7
- Issue 7
Amivantamab for EGFR-Mutated Metastatic Non–Small Cell Lung Cancer
Advertisement
Advertisement
The past decade has witnessed a dramatic shift in the treatment approach for patients with metastatic non–small cell lung cancer (mNSCLC), with the identification and understanding of EGFR mutations paving the way for numerous groundbreaking therapies.1 However, despite these advances, the 5-year overall survival (OS) rate for mNSCLC is still less than 10%.2
Related to this article
Professional membership and experienced mentor leadership offer new pharmacy technicians a dual advantage, serving as a comprehensive training accelerator.
Artificial intelligence (AI) transforms a chaotic, reactive process into an adaptive, proactive system that improves workflow and patient safety.
With nearly 8 in 10 older adults misusing at least 1 OTC product, clearer counseling and labels could close the gap.
Eight Humira biosimilars have been launched, but payer formularies and interchangeability rules decide what dispenses.
Weight-based norepinephrine dosing did not improve time to goal MAP, and median dose was similar compared with non–weight-based dosing in patients with septic shock.
At NEIAP 2026, Kelsey Norman, PharmD, walked through how VESALIUS-CV, Lp(a)HORIZON, and CKM guidelines change pharmacist-led lipid care.
The panelists emphasized that selecting a therapy is only one step toward improving outcomes for patients with heart failure.
Advertisement
Advertisement